DOCSLIB.ORG

2013 Program

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2013 Program Annual Meeting Program and Abstracts Malahide, County Dublin, Ireland June 25-30, 2013 Abstracts of the International Behavioral Neuroscience Society, Volume 22, June 2013 TABLE OF CONTENTS Abstracts..................................................................................................................... 27-113 Acknowledgments................................................................................................................5 Advertisements......................................................................................................... 115-119 Awards .................................................................................................................................3 Call for 2014 Symposium Proposals................................................................................114 Exhibitors/Sponsors .............................................................................................................4 Future Meeting .................................................................................................................114 Officers/Council...................................................................................................................2 Program/Schedule Tuesday ......................................................................................................................6 Wednesday .................................................................................................................6 Thursday ..................................................................................................................12 Friday.......................................................................................................................19 Saturday ...................................................................................................................25 Summary Program ...................................................................................Inside Back Cover IBNS CENTRAL OFFICE `tÜ|tÇÇx itÇ jtzÇxÜ? Xåxvâà|äx VÉÉÜw|ÇtàÉÜ International Behavioral Neuroscience Society 8181 Tezel Road #10269 San Antonio, Texas 78250 USA (830) 796-9393 tel. (830) 796-9394 fax (866) 377-4416 (toll-free from within the US) [email protected] http://www.ibnshomepage.org PRESIDENTIAL WELCOME Greetings from the President. Céad míle fáilte! A hundred thousand welcomes to our meeting in Ireland! As an Applachian hill-billy, I suspect that a few of my genes are Irish, and this is true of more than a few for my husband, whose genes seem to zero in on County Cork. We are meeting in the lovely sea-side town of Malahide, with Dublin and its cultural and entertainment attractions not far away, and at the beginning of summer. There is certain to be something for everyone to enjoy, at this venue …..and also at the IBNS meeting. The Program Committee has organized a lovely set of talks, symposia, and posters. Judging from the list of those already registered, this is likely to be another very well attended meeting, following on the heels of our record- breaking meeting in Hawaii last year. The core function of IBNS is to encourage research in behavioral neuroscience by fostering free and open communication and scientific exchange among its members and their academic institutions. Our meetings are the principal avenue by which this function is realized, and I am delighted to see each and every one of you here. Caroline Blanchard President, International Behavioral Neuroscience Society 1 OFFICERS President ................................................................................................................... D. Caroline Blanchard President-Elect.........................................................................................................................Stephen Kent Secretary ....................................................................................................................... Susanne Brummelte Treasurer..........................................................................................................................Stefan Brudzynski Past Presidents Kelly Lambert .............................................................................................................................. 2009-2010 Robert Gerlai ............................................................................................................................... 2007-2008 Joseph Huston ........................................................................................................................................2006 Robert Adamec ......................................................................................................................................2005 C. Sue Carter..........................................................................................................................................2004 Robert J. Blanchard................................................................................................................................2003 Mark A. Geyer .......................................................................................................................................2002 John P. Bruno.........................................................................................................................................2001 Jacqueline N. Crawley ..........................................................................................................................2000 László Lénárd.........................................................................................................................................1999 Robert L. Isaacson ................................................................................................................................1998 Michael L. Woodruff ............................................................................................................................1997 Gerard P. Smith......................................................................................................................................1996 Linda P. Spear........................................................................................................................................1995 Robert D. Myers.....................................................................................................................................1994 Paul R. Sanberg......................................................................................................................................1993 Founding President Matthew J. Wayner ................................................................................................................................1992 COUNCIL MEMBERS Australasia...............................................................................................................................Matthew Hale Australasia.................................................................................................................................. Yoichi Ueta Canada...............................................................................................................................Henry Szechtman Europe.....................................................................................................................................Anders Agmo Europe................................................................................................................................ Francesca Cirulli Latin America .........................................................................................................................Carlos Tomaz Student ...................................................................................................................................Andrew Burke USA...................................................................................................................... Francisco Gonzalez-Lima USA...................................................................................................................................... Mark B. Kristal USA........................................................................................................................................Cliff Summers 2 IBNS OUTSTANDING ACHIEVEMENT AWARD The Fellows and Honorific Awards Committee is pleased to announce the 2014 IBNS Outstanding Achievement Award for Scientific Contributions to the field of Behavioral Neuroscience is awarded to Robert J. Blanchard, Professor, University of Hawaii. Bob’s research focuses on biobehavioral emotion systems, including aggression and defense, and the behavioral and physiological consequences of social stress. He has served on the Editorial Boards of Neuroscience and Biobehavioral Reviews, Behavioral Processes, Journal of Comparative Psychology, and Pharmacology, Biochemistry & Behavior and has published over 250 journal articles. Bob also served as President of the IBNS in 2003. TRAVEL AWARDS We are pleased to announce the recipients of the IBNS Travel Awards for the 2013 meeting in Ireland. Award winners will receive a cash award, certificate, and waiver of registration fees. Travel awardees are presenting orally and will also have their research presented in a poster session. Congratulations to all. Funding for the travel awards has been provided by the generosity of Elsevier and the IBNS members. TRAVEL AWARDS (listed alphabetically) Postdoctoral Travel Awards Michal Arad, University of Maryland, Baltimore, Maryland, MD, USA Lisa Briand, University of Pennsylvania
Load more

Recommended publications
  • Different Role of CA1 5HT3 Serotonin Receptors on Memory $FTXLVLWLRQ'H¿FLW,QGXFHGE\7RWDO 76' DQG5(06OHHS 'HSULYDWLRQ 56'
    Z. Eydipour, G. Vaezi, M. Nasehi, et al. Original Article Different Role of CA1 5HT3 Serotonin Receptors on Memory $FTXLVLWLRQ'H¿FLW,QGXFHGE\7RWDO 76' DQG5(06OHHS 'HSULYDWLRQ 56' Zainab Eydipour PhD1, Gholamhassan Vaezi PhD1, Mohammad Nasehi PhDƔ, Seyed-Ali Haeri-Rouhani PhD3, Mohammad-Reza Zarrindast PhDƔ Abstract Background: Serotonin receptors such as 5-HT3 plays critical role in regulation of sleep, ZDNH cycle and cognitive process. Thus, we investigated the role of CA1 5HT3 serotonin receptors in memory acquisition GH¿FLW induced by total sleep deprivation (TSD; for 24 hour) and REM sleep deprivation (RSD; for 24 hour). Pain perception and locomotor activity were also assessed as factors that may affect the memory process. Methods: 0RGL¿HG water box and multi-platform apparatus were used to induce TSD or RSD, respectively. Passive avoidance, hot plate and open ¿HOG devices were used for assessment of memory acquisition, pain and locomotor activity, respectively. Results: Totally, 152 male Wistar rats were used in the study. Pre-training, intra-CA1 injection of 5-HT3 receptor agonist Chlorophenylbiguanide (Mchl; 0.01 and 0.001 μg/rat; P < 0.001) and antagonist Y-25130 (0.1 μg/rat; P < 0.001) reduced memory acquisition and did not alter pain response, while higher dose of both drugs increased locomotor activity in normal rats. Both TSD and RSD reduced memory acquisition (P < 0.001) and did not alter locomotor activity, while TSD (P < 0.001) but not RSD induced analgesia effect. The amnesia induced by TSD was restored by subthreshold dose of Y25130 (0.001 μg/rat; P < 0.001) but not Mchl (0.0001 μg/rat), while both drugs reversed TSD-induced analgesia effect (P < 0.01 for Mchl and P < 0.05 for Y25130), and Y25130 increased locomotor activity in TSD rats (P < 0.05).
    [Show full text]
  • Hallucinogens: an Update
    National Institute on Drug Abuse RESEARCH MONOGRAPH SERIES Hallucinogens: An Update 146 U.S. Department of Health and Human Services • Public Health Service • National Institutes of Health Hallucinogens: An Update Editors: Geraline C. Lin, Ph.D. National Institute on Drug Abuse Richard A. Glennon, Ph.D. Virginia Commonwealth University NIDA Research Monograph 146 1994 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 ACKNOWLEDGEMENT This monograph is based on the papers from a technical review on “Hallucinogens: An Update” held on July 13-14, 1992. The review meeting was sponsored by the National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other material in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors. Citation of the source is appreciated. Opinions expressed in this volume are those of the authors and do not necessarily reflect the opinions or official policy of the National Institute on Drug Abuse or any other part of the U.S. Department of Health and Human Services. The U.S. Government does not endorse or favor any specific commercial product or company.
    [Show full text]
  • Investigating the Pharmacology of Novel 5-HT3 Receptor Ligands; with the Potential to Treat Neuropsychiatric and Gastrointestinal Disorders
    Investigating the pharmacology of novel 5-HT3 receptor ligands; with the potential to treat neuropsychiatric and gastrointestinal disorders by Alexander Roberts A thesis submitted to the University of Birmingham for the Degree of Doctor of Philosophy Institute of Clinical Sciences College of Medical and Dental Sciences University of Birmingham February 2020 University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or third parties in respect of this work are as defined by The Copyright Designs and Patents Act 1988 or as modified by any successor legislation. Any use made of information contained in this thesis/dissertation must be in accordance with that legislation and must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the permission of the copyright holder. Abstract The 5-hydroxytryptamine (5-HT; serotonin) 5-HT3 receptor is an excitatory ligand- gated ion channel expressed in for example the brain and the gastrointestinal tract. Two major subtypes of the receptor have been studied in the most detail; the homomeric 5-HT3A receptor and the heteromeric 5-HT3AB receptor. 5-HT3 receptor antagonists are used clinically to treat chemotherapy induced and post-operative nausea and vomiting, and demonstrate symptomatic relief in diarrhoea-predominant irritable bowel syndrome (IBS-d); but unfortunately, these medications cause adverse effects such as constipation or rarely ischemic colitis in the latter condition. This study has characterised the pharmacology of two structurally distinct 5-HT3 receptor partial agonists (vortioxetine and CSTI-300); and identified the unique binding properties of the cryptic orthosteric modulator 5-chloroindole (Cl-indole) for the human (h) 5-HT3 receptor.
    [Show full text]
  • Proteostasis of Glial Intermediate Filaments: Disease Models, Tools, and Mechanisms
    PROTEOSTASIS OF GLIAL INTERMEDIATE FILAMENTS: DISEASE MODELS, TOOLS, AND MECHANISMS Rachel Anne Battaglia A dissertation submitted to the faculty at the University of North Carolina at Chapel Hill in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of Cell Biology and Physiology in the School of Medicine. Chapel Hill 2021 Approved by: Natasha T. Snider Carol Otey Keith Burridge Douglas Cyr Mohanish Deshmukh Damaris Lorenzo i © 2021 Rachel Anne Battaglia ALL RIGHTS RESERVED ii ABSTRACT Rachel Anne Battaglia: Proteostasis of Glial Intermediate Filaments: Disease Models, Tools, and Mechanisms (Under the direction of Natasha T. Snider) Astrocytes are a major glial cell type that is crucial for the health and maintenance of the Central Nervous System (CNS). They fulfill diverse functions, including synapse formation, neurogenesis, ion homeostasis, and blood brain barrier formation. Intermediate filaments (IFs) are components of the astrocyte cytoskeleton that support many of these functions in healthy individuals. However, upon cellular stress or genetic mutations, IF proteins are prone to accumulation and aggregation. These processes are thought to contribute to disease pathogenesis of different tissue-specific disorders, but therapeutic targeting of IFs is hindered by a lack of pharmacological tools to modulate their assembly and disassembly states. Moreover, the mechanisms that govern the formation and dissolution of IF aggregates are poorly defined. In this dissertation, I investigate IF aggregates called Rosenthal fibers (RFs), which form in astrocytes of patients with two pediatric neurodegenerative diseases, Alexander disease (AxD) and Giant Axonal Neuropathy (GAN). My aim was to gain a better understanding of the mechanisms of how astrocyte IF protein aggregates form and interrogate the role of post- translational modifications (PTMs) in this process.
    [Show full text]
  • 5-HT Receptors Review
    Neuronal 5-HT Receptors and SERT Nicholas M. Barnes1 and John F. Neumaier2 1Cellular and Molecular Neuropharmacology Research Group, Section of Neuropharmacology and Neurobiology, Clinical and Experimental Medicine, The Medical School, University of Birmingham, Edgbaston, Birmingham B15 2TT UK and 2Department of Psychiatry, University of Washington, Seattle, WA 98104 USA. Correspondence: [email protected] and [email protected] Nicholas Barnes is Professor of Neuropharmacology at the University of Birmingham Medical School, and focuses on serotonin receptors and the serotonin transporter. John Neumaier is Professor of Psychiatry and Behavioural Sciences and Director of the Division of Neurosciences at the University of Washington. His research concerns the role of serotonin receptors in emotional behavior. Contents Introduction Introduction ........................................................................ 1 5-hydroxytryptamine (5-HT, serotonin) is an ancient biochemical manipulated through evolution to be DRIVING RESEARCH FURTHER The 5-HT1 Receptor Family ............................................... 1 utilized extensively throughout the animal and plant kingdoms. Mammals employ 5-HT as a 5-HT Receptors ............................................................ 2 1A neurotransmitter within the central and peripheral nervous systems, and also as a local hormone in 5-HT Receptors ............................................................ 2 1B numerous other tissues, including the gastrointestinal tract, the cardiovascular
    [Show full text]
  • Dalwadi, Dhwanil, A, PREVENTION and TREATMENT of DISEASES: a SMALL MOLECULE DISCOVERY and DEVELOPMENT. Doctor of Philosophy (Bio
    Dalwadi, Dhwanil, A, PREVENTION AND TREATMENT OF DISEASES: A SMALL MOLECULE DISCOVERY AND DEVELOPMENT. Doctor of Philosophy (Biomedical Sciences), August, 2016, 227 pp., 6 tables, 32 illustrations, 256 references. This work examined the structure-activity relationship, and molecular mechanisms of different structural classes of small molecules at their target receptors. Three different systems were explored and each chapter is devoted to a single system. All three systems utilized similar experimental approaches, and practical application of the same core pharmacological principles. The first system involved the evaluation of the structure-activity space of small molecules acting on the α-like octopamine receptors from the barnacle Balanus improvisus (BiOctR) and the fruit fly Drosophila melanogaster (DmOctR). A number of molecules belonging to the imidazole and imidazole structural class were determined to have high potency for the BiOctR and the DmOctR. This information will be useful in designing new OctR ligands that are highly selective for the OctRs over their mammalian off-targets. Similarly, for the second system, the structure-activity space of different structural classes of sigma-1 receptor (S1R) ligands were evaluated. Four novel EPGN compounds with more than 100-fold selectivity for the S1R over the sigma-2 receptor were identified which were able to stimulate S1R-mediated BDNF secretion. Potential therapeutic applications of these compounds include the treatment of neurodegenerative diseases like Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. The third system involved the identification of receptor off-targets of efavirenz that may be responsible for efavirenz’s neuropsychiatric adverse events (NPAEs). In this study, multiple receptor targets of efavirenz belonging to the serotonin receptor family and the muscarinic receptor family of G protein-coupled receptors (GPCR) were identified, and its mechanism of action at these targets was established.
    [Show full text]
  • Novel Analogs of M-Chlorophenylguanidine As 5-HT3 Receptor Ligands
    Virginia Commonwealth University VCU Scholars Compass Theses and Dissertations Graduate School 2009 Novel Analogs of m-Chlorophenylguanidine as 5-HT3 Receptor Ligands Katie Alix Virginia Commonwealth University Follow this and additional works at: https://scholarscompass.vcu.edu/etd Part of the Chemicals and Drugs Commons © The Author Downloaded from https://scholarscompass.vcu.edu/etd/1734 This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. © Katie Elizabeth Alix 2008 All Rights Reserved NOVEL ANALOGS OF m-CHLOROPHENYLGUANIDINE AS 5-HT3 RECEPTOR LIGANDS A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science at Virginia Commonwealth University. by KATIE ELIZABETH ALIX Bachelor of Science in Biochemistry, Virginia Tech 2006 Bachelor of Arts in Chemistry, Virginia Tech 2006 Director:MAŁGORZATA DUKAT Associate Professor, Department of Medicinal Chemistry Virginia Commonwealth University Richmond, Virginia May 2009 Acknowledgement First, I would like to thank Dr. Dukat for her patience and guidance over the last three years. She has helped mold me into a better scientist with a deeper understanding and appreciation of medicinal chemistry as an entire discipline. I would like to thank Dr. Richard Glennon for his help with my thesis and numerous useful insights. I would also like to thank Dr. Richard Young, Jessica Worsham, and Genevieve Sirles for teaching me how to handle mice and the various animal assays. I would also like to thank Dr.
    [Show full text]
  • Review Article Choosing an Animal Model for the Study of Functional Dyspepsia
    Hindawi Canadian Journal of Gastroenterology and Hepatology Volume 2018, Article ID 1531958, 13 pages https://doi.org/10.1155/2018/1531958 Review Article Choosing an Animal Model for the Study of Functional Dyspepsia Yang Ye,1,2 Xue-Rui Wang,1 Yang Zheng,1 Jing-Wen Yang ,1 Na-Na Yang,1,2 Guang-Xia Shi,1 and Cun-Zhi Liu 1 1 Acupuncture and Moxibustion Department, Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University, Beijing Key Laboratory of Acupuncture Neuromodulation, Beijing, China 2Beijing University of Chinese Medicine, Beijing, China Correspondence should be addressed to Cun-Zhi Liu; [email protected] Received 9 September 2017; Accepted 16 November 2017; Published 12 February 2018 Academic Editor: Yousuke Nakai Copyright © 2018 Yang Ye et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Functional dyspepsia (FD) is a common functional gastrointestinal disorder with pain or discomfort in the upper abdomen as the main characteristic. The prevalence of FD worldwide varies between 5% and 11%. This condition adversely affects attendance and productivity in the workplace. Emerging evidence is beginning to unravel the pathophysiologies of FD, and new data on treatment are helping to guide evidence-based practice. In order to better understand the pathophysiologies of FD and explore better treatment options, various kinds of animal models of FD have been developed. However, it is unclear which of these models most closely mimic the human disease. This review provides a comprehensive overview of the currently available animal models of FD in relationship to the clinical features of the disease.
    [Show full text]
  • Serotonin Receptors and Drugs Affecting Serotonergic Neurotransmission R ICHARD A
    Chapter 11 Serotonin Receptors and Drugs Affecting Serotonergic Neurotransmission R ICHARD A. GLENNON AND MAŁGORZATA DUKAT Drugs Covered in This Chapter* Antiemetic drugs (5-HT3 receptor • Rizatriptan • Imipramine antagonists) • Sumatriptan • Olanzapine • Alosetron • Zolmitriptan • Propranolol • Dolasetron Drug for the treatment of • Quetiapine • Granisetron irritable bowel syndrome (5-HT4 • Risperidone • Ondansetron agonists) • Tranylcypromine • Palonosetron • Tegaserod • Trazodone • Tropisetron Drugs for the treatment of • Ziprasidone Drugs for the treatment of neuropsychiatric disorders • Zotepine migraine (5-HT1D/1F receptor agonists) • Buspirone Hallucinogenic agents • Almotriptan • Citalopram • Lysergic acid diethylamide • Eletriptan • Clozapine • 2,5-dimethyl-4-bromoamphetamine • Frovatriptan • Desipramine • 2,5-dimethoxy-4-iodoamphetamine • Naratriptan • Fluoxetine Abbreviations cAMP, cyclic adenosine IBS-C, irritable bowel syndrome with nM, nanomoles/L monophosphate constipation MT, melatonin CNS, central nervous system IBS-D, irritable bowel syndrome with MTR, melatonin receptor 5-CT, 5-carboxamidotryptamine diarrhea NET, norepinephrine reuptake transporter DOB, 2,5-dimethyl-4-bromoamphetamine LCAP, long-chain arylpiperazine 8-OH DPAT, 8-hydroxy-2-(di-n- DOI, 2,5-dimethoxy-4-iodoamphetamine L-DOPA, L-dihydroxyphenylalanine propylamino)tetralin EMDT, 2-ethyl-5-methoxy-N,N- LSD, lysergic acid diethylamide PMDT, 2-phenyl-5-methoxy-N,N- dimethyltryptamine MAO, monomaine oxidase dimethyltryptamine GABA, g-aminobutyric acid MAOI,
    [Show full text]
  • Journal of Liquid Chromatography & Related Technologies 1996
    JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES HPLC TLC Capillary Electrophoresis Supercritical Fluid Techniques Membrane Technology Field-Flow Fractionation Preparative & Analytical Separations formerly Journal of Liquid Chromatography JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES April 1996 Aims and Scope. The journal publishes an outstanding selection of critical, peer- reviewed papers dealing with analytical, preparative and process-scale liquid chromatography of all types and related technologies such as TLC; capillary electrophoresis; supercritical fluid extraction and chromatography; membrane separation technology; field-flow techniques; and others. As new separation technologies are introduced, they will also be included in the journal. On a regular basis, special topical issues are devoted to specific technologies and applications. Book reviews, software reviews and a calendar of meetings, symposia and expositions are also included. Identification Statement. Journal of Liquid Chromatography & Related Technologies (ISSN: 1082-6076) is published semimonthly except monthly in May, August, October, and December for the institutional rate of $1,595.00 and the individual rate of $797.50 by Marcel Dekker, Inc., P.O. Box 5005, Monticello, NY 12701-5185. Second Class postage paid at Monticello, NY. POSTMASTER: Send address changes to Journal of Liquid Chromatography & Related Technologies, P.O. Box 5005, Monticello, NY 12701-5185. Individual Foreign Postage Professionals’ Institutional and Student Airmail Airmail Volume Issues Rate Rate Surface to Europe to Asia 19 20 $1,595.00 $797.50 $70.00 $110.00 $130.00 Individual professionals’ and student orders must be prepaid by personal check or may be charged to MasterCard, VISA, or American Express. Please mail payment with your order to: Marcel Dekker Journals, P.O.
    [Show full text]
  • Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice
    0031-6997/06/5803-521–590$20.00 PHARMACOLOGICAL REVIEWS Vol. 58, No. 3 Copyright © 2006 by The American Society for Pharmacology and Experimental Therapeutics 60305/3134736 Pharmacol Rev 58:521–590, 2006 Printed in U.S.A Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice SHARON J. GARDINER AND EVAN J. BEGG Department of Medicine, Christchurch School of Medicine and Health Sciences, Christchurch, New Zealand Abstract ............................................................................... 523 I. Introduction/perspective ................................................................. 523 A. Background on pharmacogenetics ..................................................... 524 B. Pathways with genetic variation that may be important clinically ........................ 526 II. Cytochrome P450 ....................................................................... 526 A. CYP2D6 ............................................................................ 526 1. Tricyclic antidepressants .......................................................... 526 a. Amitriptyline (tertiary)/nortriptyline (secondary) .................................. 529 b. Imipramine (tertiary)/desipramine (secondary).................................... 530 c. Clomipramine (tertiary)/desmethylclomipramine (secondary) ....................... 531 d. Doxepin (tertiary)/desmethyldoxepin (secondary) .................................. 531 2. Selective serotonin reuptake inhibitors.............................................. 531 a. Fluoxetine ...................................................................
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION 1-(3-Chlorophenyl)biguanide (hydrochloride) Item No. 34726 CAS Registry No.: 2113-05-5 Formal Name: N-(3-chlorophenyl)-imidodicarbonimidic diamide, monohydrochloride Synonyms: m-Chlorophenylbiguanide, meta-Chlorophenylbiguanide, NH NH m-CPBG, meta-CPBG MF: C8H10ClN5 • HCl Cl N N NH2 FW: 248.1 H H Purity: ≥95% • HCl UV/Vis.: λmax: 257 nm Supplied as: A solid Storage: -20°C Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures 1-(3-Chlorophenyl)biguanide (m-CPBG) (hydrochloride) is supplied as a solid. A stock solution may be made by dissolving the m-CPBG in the solvent of choice, which should be purged with an inert gas. m-CPBG (hydrochloride) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of m-CPBG (hydrochloride) in these solvents is approximately 5, 20, and 30 mg/ml, respectively. Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of m-CPBG (hydrochloride) can be prepared by directly dissolving the solid in aqueous buffers. The solubility of m-CPBG (hydrochloride) in PBS (pH 7.2) is approximately 5 mg/ml. We do not recommend storing the aqueous solution for more than one day. Description 1 m-CPBG is an agonist of the serotonin (5-HT) receptor subtype 5-HT3. It selectively binds 5-HT3 over 5-HT1A and 5-HT2 receptors (Kis = 0.002, 10, and 10 µM, respectively) but also binds to high and low affinity sites on the dopamine transporter (DAT; IC50s = 0.4 and 34.8 µM, respectively, in rat caudate putamen synaptosomal membranes).2,3 m-CPBG induces depolarization of isolated rat vagus nerve and stimulates 1,4 inositol phosphate formation in rat frontocingulate cortical slices (EC50s = 0.05 and 4.2 µM, respectively).
    [Show full text]